Periodic Reporting for period 2 - TANTUMorNEUVACCINE (Neutrophil subtypes: distinct cellular targets for therapeutic intervention)

Many patients with tumors do not respond to immune therapies - such as anti-PD-1 immune checkpoint blockade - because of a lack of pre-existing inflammation that is required for those therapies to work. We decided to reprogram regulatory T cells (Treg) specifically in tumors...